Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$52.72 USD
+1.13 (2.19%)
Updated Nov 7, 2024 12:20 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
AGIO 52.72 +1.13(2.19%)
Will AGIO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGIO
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
Other News for AGIO
Analysts’ Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)
Agios Pharmaceuticals to present new data on mitapivat, tebapivat
Agios Pharmaceuticals to present new data on mitapivat, tebapivat
Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)
Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank